While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are three cash-producing companies that don’t make the cut and some better opportunities instead.

Nike (NKE)

Trailing 12-Month Free Cash Flow Margin: 2.3%

Originally selling Japanese Onitsuka Tiger sneakers as Blue Ribbon Sports, Nike (NYSE: NKE) is a global titan in athletic footwear, apparel, equipment, and accessories.

Why Do We Think NKE Will Underperform?

1. Underwhelming constant currency revenue performance over the past two years suggests its product offering at current prices doesn’t resonate with customers
2. Free cash flow margin is expected to increase by 1.6 percentage points next year, suggesting the company will have more capital to invest or return to shareholders
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

Nike is trading at $42.68 per share, or 26.9x forward P/E. Read our free research report to see why you should think twice about including NKE in your portfolio.

AT&T (T)

Trailing 12-Month Free Cash Flow Margin: 15.5%

Founded by Alexander Graham Bell, AT&T (NYSE: T) is a multinational telecomm conglomerate providing a range of communications and internet services.

Why Should You Dump T?

1. Sales were flat over the last five years, indicating it’s failed to expand its business
2. Earnings per share fell by 7.9% annually over the last five years while its revenue was flat, showing each sale was less profitable
3. Capital intensity will likely ramp up in the next year as its free cash flow margin is expected to contract by 1.4 percentage points

AT&T’s stock price of $26.48 implies a valuation ratio of 11.7x forward P/E. Dive into our free research report to see why there are better opportunities than T.

Zimmer Biomet (ZBH)

Trailing 12-Month Free Cash Flow Margin: 14.2%

With a history dating back to 1927 and a presence in over 100 countries worldwide, Zimmer Biomet (NYSE: ZBH) designs and manufactures orthopedic products including knee and hip replacements, surgical tools, and robotic technologies for joint reconstruction and spine surgeries.

Why Is ZBH Not Exciting?

1. 4.5% annual revenue growth over the last five years was slower than its healthcare peers
2. Estimated sales growth of 3.9% for the next 12 months implies demand will slow from its two-year trend
3. ROIC of 4.1% reflects management’s challenges in identifying attractive investment opportunities

At $93.50 per share, Zimmer Biomet trades at 11.1x forward P/E. Check out our free in-depth research report to learn more about why ZBH doesn’t pass our bar.

Stocks We Like More

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.